Telix Pharmaceuticals Limited (TLX.AX) News
Track canonical SquawkNews coverage tagged to TLX.AX, Telix Pharmaceuticals Limited. This hub brings together deduplicated headlines about asx, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
BUZZ — Australia's Telix set for best week in 7 months after FDA nod for drug
* Shares of Telix Pharmaceuticals gain as much as 3.8% to A$18.110 * Stock on track to log 14.6% gain for the week, its strongest since the week ended February 20 * Biopharma co said on Monday the US Food and Drug Admini
REGULATION | Sep 18, 2026, 02:22 AM UTC
H
Telix Pharmaceuticals price target lowered to $22 from $22.50 at Citi
Citi lowered the firm's price target on Telix Pharmaceuticals to $22 from $22.50 and keeps a Buy rating on the shares. Q2 Visible Alpha consensus of $184M in Illuccix/Gozellix sales "looks reasonable," says the analyst,
EQUITY | Jul 07, 2026, 04:51 PM UTC